Idéal Investisseur
Français English
CAC 40 :
8 157,82 pts
-0.84%


Last updated : 24/04/2026 - 17h35
🏠 Home   ➤    Stock news

DBV Technologies Stock Up +187% Over the Year and Testing a Key Technical Threshold

DBV Technologies rose 4.59% this Wednesday morning to €3.69, in a Parisian market buoyed by a CAC 40 that surged 3.97% during the session. The biotech company specializing in food allergies now shows a performance increase of over 187% over the year, following a path marked by a strong upward dynamic in recent months.


DBV Technologies Stock Up +187% Over the Year and Testing a Key Technical Threshold

Technical Analysis of DBV Technologies' Current Position

This morning, DBV Technologies' stock is trading at €3.69, up 4.59% from yesterday's close of €3.53. This rebound brings the price to the immediate vicinity of its 50-day moving average at €3.70, a technical threshold whose sustained crossing could confirm the resumption of a positive short-term trend. The 200-day moving average, significantly lower at €2.62, reflects the strength of the bullish movement over the last twelve months. The RSI, at 45, is in a neutral zone, indicating that the stock is neither overbought nor oversold. In the Bollinger Bands, the price is in the upper part of the channel (65% between the lower bound at €3.17 and the upper bound at €3.97), yet without approaching the upper bound, leaving room for progression before reaching a tension signal. The next identifiable resistance threshold is at €4.04.

DBV Technologies' Market Recovery and Stock Performance

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
Before 9 AM every morning Euronext data AI-powered analysis

With an increase of 20.39% over three months and 187.4% over a year, DBV Technologies stands out for the magnitude of its stock market recovery. The stock has a beta of 0.33, indicating very limited sensitivity to fluctuations in major indices. This decoupled profile contrasts with the day's performance of the CAC 40, which is up nearly 4% in a session marked by high volatility due to major geopolitical developments. The SBF 120 is up similarly by 3.92%. Other stocks in the biotechnology and pharmaceutical sector show much more moderate variations this Wednesday morning: Sanofi is up 0.37% and UCB is up 0.95%. The one-month volatility of DBV Technologies, measured at 22.35, remains significant for a stock of this capitalization but continues a trajectory marked by sometimes broad movements. No events are announced in the company's financial calendar in the short term.



Sector Santé · Biotechnologies · Pharmacie Biotechnologie


Assurance vie

Context

Period
  • Period: 3T 2025
Guidance from the release
  • Perte nette trimestrielle de (33,2) millions de dollars ; trésorerie de 69,8 millions de dollars au 30/09/2025 suite à un financement partiel (125,5 M$ reçu) et un programme ATM ; dépenses opérationnelles élevées principalement en R&D (83,8 M$ sur 9 mois). Trésorerie estimée suffisante jusqu'au T3 2026 mais incertitude significative persiste.
Risks mentioned
  • Incertitude significative sur la continuité d'exploitation (trésorerie insuffisante pour couvrir 12 prochains mois)
  • Dépendance aux financements externes (PIPE, ATM et autres levées de fonds)
  • Accès futur aux capitaux soumis aux conditions du marché et à l'intérêt des investisseurs
  • Dépendance aux résultats de l'étude de phase 3 VITESSE pour accélération d'exercices de BSA et financements supplémentaires
Opportunities identified
  • Financement pouvant atteindre 306,9 millions de dollars via PIPE
  • Programme ATM pouvant générer jusqu'à 150,0 millions de dollars
  • Potentiel réglementaire et commercial du patch Viaskin® Peanut (BLA et lancement aux États-Unis si approuvé)
  • Possibilité d'exercices supplémentaires de bons de souscription si certains critères sont atteints

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
Avant 9h00 1000+ inscrits 100% gratuit